< Back to previous page
Researcher
Michel Delforge
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Jan 2021 → Today - Stem Cell and Developmental Biology (Division)
Member
From1 Apr 2013 → 31 Dec 2020 - Faculty of Medicine (Faculty)
Member
From1 Oct 2000 → 30 Sep 2002
Projects
1 - 10 of 19
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing the use of bispecific antibody treatment in Multiple Myeloma by studying the immune microenvironment and cellular mechanisms of drug resistance.From1 Oct 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Oct 2023 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Positron emission tomography combined with innovative laboratory techniques for improved risk and disease assessment in myeloma.From1 Jan 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Risk prediction and modeling of cancer therapy related cardiotoxicityFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Atomic Force Microscopy Enhanced Spectroscopy to Study Strains and Seeding of Amyloids In SituFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Augmenting THherapeutic Effectiveness through Novel AnalyticsFrom1 Apr 2020 → 31 Dec 2023Funding: VLAIO - Personalised Medicine ICON
- Het KU Leuven Kankerinstituut (LKI): interdisciplinaire samenwerking ter bevordering van kankeronderzoek, kankerbehandeling en –zorg.From1 Jan 2020 → TodayFunding: BOF - research organisations
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myeloma.From1 Jul 2019 → 30 Jun 2023Funding: Foundations, funds and other with scientific goal
Publications
11 - 20 of 265
- Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis(2023)
Authors: Michel Delforge
- Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients(2023)
Authors: Michel Delforge
- Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study(2023)
Authors: Michel Delforge
- Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study(2023)
Authors: Michel Delforge
Pages: 181 - 190 - Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)(2023)
Authors: Michel Delforge
Pages: 1175 - 1185 - Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial(2023)
Authors: Michel Delforge
- Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network(2023)
Authors: Michel Delforge
Pages: E255 - E269 - Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma(2023)
Authors: Michel Delforge
Pages: 2412 - 2425 - Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma(2023)
Authors: Michel Delforge
Pages: 811 - 818 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma(2023)
Authors: Michel Delforge
Pages: 1002 - 1014
Patents
1 - 2 of 2
- Cell therapy for myelodysplastic syndromes (Inventor)
- CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES (Inventor)